Sexual and Urinary Dysfunctions in Generalized Myasthenia
NCT07677852 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 150
Last updated 2026-07-01
Summary
Myasthenia gravis is an autoimmune disease caused by specific autoantibodies that disrupt the function of the neuromuscular junction. It manifests as excessive fatigue of the skeletal muscles during physical exertion and affects 15,000 people in France. Initial symptoms are most often ocular (ptosis, diplopia) but can later spread throughout the body, potentially leading in some cases to respiratory failure and/or swallowing difficulties (myasthenic crisis) or even death. This condition is currently being managed more effectively through treatment, and the invisible symptoms (sexual dysfunction, sphincter dysfunction, psychological impact, etc.) may ultimately be more debilitating than the initial symptoms, which are often controlled by maintenance and/or symptomatic treatments. The impact of myasthenia gravis on intimate life remains a taboo subject and is poorly understood by both the medical community and patients. In the literature, only a single article from 2021 addresses sexual dysfunction in patients with myasthenia gravis. Urinary disorders in myasthenia gravis are frequently reported but have also been little studied.
A national survey, conducted using an online questionnaire distributed by patient associations, shed light on the disease's impact on patients' intimate lives. In this study of 190 patients, 46 of them responded to the question about sexual function, and one in two patients reported sexual complaints; in 46% of cases, this disorder significantly impacted the patients' daily lives. In particular, a decrease in the frequency of sexual intercourse with a partner was noted in 55% of cases, as well as a decrease in sexual desire in 51% of cases.
Sexual dysfunction is very common and underreported in many chronic neurological diseases. The Sexual Complaints Screener (SCS W/M) questionnaires for women and men in English have very recently been validated in French (Questionnaires de Plaintes Sexuelles, QPS F/H).
It now have a 10-item self-administered questionnaire that assesses the full range of sexual disorders and their impact.
In conclusion, while the visible symptoms of myasthenia gravis are widely recognized, the invisible symptoms-such as genitourinary and sphincter disorders-remain largely unrecognized and underdiagnosed. It is therefore essential to conduct systematic screening in order to best guide our patients and thereby improve their quality of life.
Conditions
- Myasthenia Gravis (MG)
Interventions
- OTHER
-
No intervetion
no intervention
Sponsors & Collaborators
-
Centre Hospitalier Universitaire de Nice
lead OTHER
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2026-07-30
- Primary Completion
- 2030-07-30
- Completion
- 2030-07-30
Countries
- France
Study Locations
More Related Trials
-
Myasthenia Gravis Registry in China
NCT06241521 ·Status: RECRUITING
-
The Evaluation of Belimumab in Myasthenia Gravis (MG)
NCT01480596 ·Status: COMPLETED ·Phase: PHASE2
-
Monitor the Evolution of Myasthenia Gravis Symptoms in Real-life in Patients With Anti-AChR and Anti-MUSK Generalised Myasthenia Gravis in Therapy With RYSTIGGO® (Rozanolixizumab)
NCT07570589 ·Status: RECRUITING
-
Study to Test the Safety, Tolerability and Efficacy of UCB7665 in Subjects With Moderate to Severe Myasthenia Gravis
NCT03052751 ·Status: COMPLETED ·Phase: PHASE2
-
Immune Profiles in Myasthenia Gravis
NCT05095103 ·Status: UNKNOWN
-
Expediting Myasthenia Gravis (MG) Diagnostic Evaluation: A Novel, Proof-of-Concept for Undiagnosed, Symptomatic Patients That Uses Social Media Targeting and Self-Assessment
NCT06381284 ·Status: COMPLETED
-
Immediate Corticosteroid Therapy and Rituximab to Prevent Generalization in Ocular Myasthenia: a PROBE Multicenter Open-label Randomized Controlled Trial.
NCT06342544 ·Status: RECRUITING ·Phase: PHASE3
-
Safety and Efficacy Study of Eculizumab in Patients With Refractory Generalized Myasthenia Gravis
NCT00727194 ·Status: TERMINATED ·Phase: PHASE2
-
Characteristics and Prognostic Outcomes of Diaphragmatic Ultrasound in Myasthenia Gravis
NCT06707727 ·Status: ACTIVE_NOT_RECRUITING
-
Clinical and Laboratory Profile of Myasthenia Gravis in Children At Sohag University Hospitals
NCT06774937 ·Status: NOT_YET_RECRUITING
-
Efficacy and Safety of Vaccination Against COVID-19 in Neuromuscular Patients
NCT05311904 ·Status: COMPLETED
-
OVEMP in Myasthenia
NCT03049956 ·Status: COMPLETED ·Phase: NA
-
A Pilot Trial of Rituxan in Refractory Myasthenia Gravis
NCT00619671 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
A Prospective Cohort Study of Myasthenia Gravis in China
NCT06006832 ·Status: RECRUITING
-
Adult Autoimmune Myopathies (MAIA)
NCT04792931 ·Status: RECRUITING ·Phase: NA
-
A Study to Evaluate the Efficacy and Safety of Rozanolixizumab in Adult Participants With Ocular Myasthenia Gravis
NCT07463521 ·Status: RECRUITING ·Phase: PHASE3
-
Validation and Scaling of Screening Program for Undiagnosed Myasthenia Gravis-Social Media Campaign Paired With a Self-moderated Assessment
NCT06866483 ·Status: RECRUITING
-
Disease-Modifying Treatments for Myasthenia Gravis
NCT03490539 ·Status: COMPLETED
-
Proteomic Changes in Patients With Myasthenia Gravis and Ravulizumab
NCT07337395 ·Status: NOT_YET_RECRUITING
-
Exploring Outcomes and Characteristics of Myasthenia Gravis 2
NCT06002945 ·Status: COMPLETED
-
The Impact of Myasthenia Gravis in the Real World
NCT04176211 ·Status: COMPLETED
-
A Study to Test Efficacy and Safety of Rozanolixizumab in Adult Patients With Generalized Myasthenia Gravis
NCT03971422 ·Status: COMPLETED ·Phase: PHASE3
-
Precision Diagnosis and Prospective Cohort Study for Myasthenia Gravis: Multicenter Analysis in China
NCT04535843 ·Status: RECRUITING
-
An Efficacy and Safety Study of ARGX-113 in Patients With Myasthenia Gravis Who Have Generalized Muscle Weakness
NCT03669588 ·Status: COMPLETED ·Phase: PHASE3
-
Safety and Efficacy Study of Ravulizumab in Adults With Generalized Myasthenia Gravis
NCT03920293 ·Status: COMPLETED ·Phase: PHASE3